Park Avenue Securities LLC Boosts Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Park Avenue Securities LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 39.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,701 shares of the company’s stock after purchasing an additional 760 shares during the period. Park Avenue Securities LLC’s holdings in Medpace were worth $897,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in MEDP. Iron Triangle Partners LP purchased a new stake in shares of Medpace in the 3rd quarter valued at about $64,371,000. Clearbridge Investments LLC raised its stake in shares of Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after acquiring an additional 143,481 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock worth $127,941,000 after acquiring an additional 119,257 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its holdings in shares of Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after purchasing an additional 105,659 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. TD Cowen lowered their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Robert W. Baird upped their price objective on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Finally, UBS Group cut Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $380.56.

Medpace Stock Up 3.0 %

Shares of Medpace stock opened at $347.52 on Wednesday. Medpace Holdings, Inc. has a 52 week low of $286.76 and a 52 week high of $459.77. The stock’s 50-day simple moving average is $340.00 and its 200-day simple moving average is $356.52. The company has a market capitalization of $10.80 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 1.73 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.22 earnings per share. On average, equities analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.